The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! About 587,113 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 29.54% since March 2, 2016 and is uptrending. It has outperformed by 21.28% the S&P500.
The move comes after 8 months positive chart setup for the $2.15B company. It was reported on Oct, 5 by Barchart.com. We have $88.82 PT which if reached, will make NYSE:PBYI worth $666.50M more.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 earnings per share, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual earnings per share reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 21. RBC Capital Markets downgraded the shares of PBYI in a report on Tuesday, March 29 to “Sector Perform” rating. The firm has “Overweight” rating given on Tuesday, March 29 by JP Morgan. The firm has “Neutral” rating given on Thursday, September 3 by Citigroup. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The firm has “Buy” rating by Citigroup given on Monday, December 14. The firm has “Outperform” rating by Credit Suisse given on Tuesday, March 29. Citigroup maintained Puma Biotechnology Inc (NYSE:PBYI) on Tuesday, March 29 with “Buy” rating. The stock has “Outperform” rating given by Credit Suisse on Thursday, September 22. The firm has “Buy” rating by UBS given on Monday, April 11.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.18, from 1.03 in 2016Q1. The ratio improved, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Eaton Vance Mngmt holds 142,000 shares or 0.01% of its portfolio. State Of New Jersey Common Pension Fund D last reported 25,833 shares in the company. Alliancebernstein Lp holds 46,840 shares or 0% of its portfolio. State Board Of Administration Of Florida Retirement has 17,123 shares for 0% of their US portfolio. State Street Corp has 1.06 million shares for 0% of their US portfolio. Bb Biotech Ag holds 0.51% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 431,991 shares. Moreover, Federated Invsts Inc Pa has 0% invested in Puma Biotechnology Inc (NYSE:PBYI) for 50,139 shares. Moreover, Citigroup Incorporated has 0% invested in Puma Biotechnology Inc (NYSE:PBYI) for 2,291 shares. Capital Research has 676,600 shares for 0.01% of their US portfolio. Partner Invest Mngmt Lp holds 22,740 shares or 1.11% of its portfolio. Wellington Management Grp Inc Ltd Liability Partnership owns 12,623 shares or 0% of their US portfolio. The Connecticut-based Cubist Systematic Strategies Ltd Liability Corp has invested 0.01% in Puma Biotechnology Inc (NYSE:PBYI). Nationwide Fund Advsr last reported 16,108 shares in the company. New York State Common Retirement Fund has invested 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Bogle Inv Mngmt L P De holds 0.82% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 395,750 shares.
More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Equitiesfocus.com which released: “Puma Biotechnology Inc (NYSE:PBYI) Reported Basic Consolidated EPS Of $-7.4483” on April 20, 2016, also Fool.com with their article: “Why Puma Biotechnology Inc Roared Higher Today” published on September 20, 2016, Nasdaq.com published: “Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against …” on October 04, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Fool.com and their article: “Why Puma Biotechnology, Inc. Stock Soared 65.1% in July” published on August 04, 2016 as well as Fool.com‘s news article titled: “Why Puma Biotechnology, Inc. Stock Crashed 37% in March” with publication date: April 11, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.